BeiGene (BGNE) Stock Forecast & Price Target

$162.54

-0.73 (-0.45%)

(As of 07/26/2024 ET)

BeiGene - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 10 Analyst Ratings

Based on 10 Wall Street analysts who have issued ratings for BeiGene in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 2 have given a hold rating, and 8 have given a buy rating for BGNE.

Consensus Price Target

$250.75
54.27% Upside

High Forecast	$345.00
Average Forecast	$250.75
Low Forecast	$152.50

According to the 10 analysts' twelve-month price targets for BeiGene, the average price target is $250.75. The highest price target for BGNE is $345.00, while the lowest price target for BGNE is $152.50. The average price target represents a forecasted upside of 54.27% from the current price of $162.54.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$250.75	$251.93	$250.13	$278.43
Forecasted Upside	54.27% Upside	40.20% Upside	41.09% Upside	26.03% Upside

Get BeiGene Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.

Ad Unstoppable Prosperity

“Generational Bull Run” Incoming

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

You can find out what they are by clicking here now.

BGNE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BGNE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BeiGene Stock vs. The Competition

Type	BeiGene	Medical Companies	S&P 500
Consensus Rating Score	2.80	2.72	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	54.27% Upside	3,123.46% Upside	9.18% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
7/9/2024	Bank of America 4 of 5 stars	Lower Target	Neutral ➝ Neutral	$180.00 ➝ $152.50	+5.82%
5/9/2024	TD Cowen 4 of 5 stars	Boost Target	Buy ➝ Buy	$236.00 ➝ $254.00	+51.95%
3/27/2024	Sanford C. Bernstein 3 of 5 stars	Lower Target	Market Perform ➝ Market Perform	$196.00 ➝ $161.00	+4.67%
3/19/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$184.00 ➝ $186.00	+10.79%
2/27/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$350.00 ➝ $345.00	+98.62%
10/26/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$290.00 ➝ $285.00	+72.27%
Get the Latest News and Ratings for BGNE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for BeiGene and its competitors with MarketBeat's FREE daily newsletter.
9/12/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$259.00	+25.82%
9/11/2023	Macquarie Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$259.00	+23.78%
8/29/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$321.00 ➝ $319.00	+50.44%
8/17/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$287.00	+49.22%
6/30/2023	51job Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Downgrade
6/30/2023	22nd Century Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Downgrade
6/30/2023	3M Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Downgrade
2/28/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform	$213.00 ➝ $262.00	+21.28%
1/20/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform	$236.00 ➝ $300.00	+9.29%
1/11/2023	Daiwa Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$308.00	+20.87%
11/10/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$200.00 ➝ $213.00	+13.39%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:30 AM ET.

BGNE Forecast - Frequently Asked Questions

What is BeiGene's forecast for 2024?: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for BeiGene is $250.75, with a high forecast of $345.00 and a low forecast of $152.50.
Should I buy or sell BeiGene stock right now?: 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BGNE shares.
Does BeiGene's stock price have much upside?: According to analysts, BeiGene's stock has a predicted upside of 39.96% based on their 12-month stock forecasts.
What analysts cover BeiGene?: BeiGene has been rated by research analysts at Bank of America, and TD Cowen in the past 90 days.
Do Wall Street analysts like BeiGene more than its competitors?: Analysts like BeiGene more than other "medical" companies. The consensus rating score for BeiGene is 2.80 while the average consensus rating score for "medical" companies is 2.72. Learn more on how BGNE compares to other companies.